REFERENCES: 
  1. Kusumakumari P, Ajithkumar TV, Ratheesan K, Chellam VG, Nair MK. Pattern and outcome of neuroblastoma. A 10 year study. Indian Pediatr 1998; 35: 223-229.
  2. Bansal D, Marwaha RK, Trehan A, Rao KL, Gupta V. Profile and outcome of neuroblastoma with conventional chemotherapy in children older than one year: a 15 y experience. Indian Pediatr. 2008;45:135–9.
  3. Agarwala S, Mandelia A, Bakhshi S, et al. Neuroblastoma: out- come over a 14 y period from a tertiary care referral centre in India. J Pediatr Surg. 2014;49:1280–5.
  4. Lucena JN, Alves MTS, Abib SCV, Souza GO, Neves RPC, Caran EMM. Clinical and epidemiological  characteristics and survival outcomes of children with neuroblastoma: 21 years of experience at the Instituto de Oncologica Pediatrica, in São Paulo, Brazil. Rev Paul Pediatr. 2018;36:254-260.
  5. Aydn GB, Kutluk MT, Yalçn B, Büyükpamukçu M, Kale G, Varan A, Akyüz C, Senocak ME, Büyükpamukçu N. Neuroblastoma in Turkish children: experience of a single center. J Pediatr Hematol Oncol. 2009;31:471-80.
  6. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK; International Society of Pediatric Oncology. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62:1305-16.
  7. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016; 65:1-10.
  8. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O’Leary M, Gerbing RB, Matthay KK. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children’s Cancer Group Study. J Clin Oncol. 2005;23:6474-80.
  9. Moroz V, Machin D, Hero B, et al. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020;e28359. https://doi.org/10.1002/pbc.28359
  10. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991;9:1050-8.
  11. Kusumakumari P, Ajithkumar TV, Hariharan S, Varma RR, Chellam VG, Nair R, et al. Intensive chemotherapy in children with stage IV neuroblastoma. Indian J Pediatr 1999; 66: 867-872.
  12. Richa Jain , Amita Trehan , Prema Menon et al. Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta. Pediatr Hematol Oncol 2021;1-13. doi: 10.1080/08880018.2020.1850955.
  13. Simon T, Häberle B, Hero B, Dietrich von Schweinitz, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol. 2013 ;31(6):752-8. doi: 10.1200/JCO.2012.45.9339. Epub 2013 Jan 2.